Pronostic and therapeutic consequences of G(s)α mutations in somatotroph adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 5, 1998, Pages 1604-1610

  Barlier, Anne ^a,c   Gunz, Ginette ^a   Zamora, Alfredo J ^a   Morange Ramos, Isabelle ^a,b   Figarella Branger, Dominique ^b   Dufour, Henri ^b   Enjalbert, Alain ^a   Jaquet, Philippe ^a,b  

^a URA CNRS 1455   (France)

^b TIMONE HOSPITAL   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GUANINE NUCLEOTIDE BINDING PROTEIN; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; GENE MUTATION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOCYTOCHEMISTRY; ONCOGENE; POINT MUTATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; SOMATIC CELL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ANTINEOPLASTIC AGENTS, HORMONAL; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMAN GROWTH HORMONE; HUMANS; KINETICS; MUTATION; OCTREOTIDE; PITUITARY NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031724241     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.5.1604     Document Type: Article

References (32)

1. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, L Vallar. 1989 GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 340:692-696.
2. Vallar L, Spada A, Giannattasio G. 1987 Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Science. 330:566-568.
3. Landis CA, Harsh G, Lyons J, Davis RL, McCormick F, Bourne HR. 1990 Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J Clin Endocrinol Metab. 71:1416-1420.
4. Spada A, Arosio M, Bochicchio D, et al. 1990 Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab. 71:1421-1426.
5. Harris PE, Alexander JM, Bikkal HA, et al. 1992 Glycoprotein hormone α-subunit production in somatotroph adenomas with and without Gsα mutations. J Clin Endocrinol Metab. 75:918-923.
6. Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M, Fahlbusch R. 1993 Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery. 33:198-203.
7. Adams EF, Lei T, Buchfelder M, Petersen B, Fahlbusch R. 1995 Biochemical characteristics of human pituitary somatotropinomas with and without gsp mutations: in vitro cell culture studies. J Clin Endocrinol Metab. 80:2077-2081.
8. Yang I, Park S, Ryu M, et al. 1996 Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol. 134:720-726.
9. Morange-Ramos I, De Boisvilliers F, Chanson P, et al. 1994 Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 79:145-151.
10. Hosoi E, Yokogoshi Y, Hosoi E, et al. 1993 Analysis of the Gsα gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues. Acta Endocrinol (Copenh). 129:301-306.
11. Faglia G, Arosio M, Spada A. 1996 Gs protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. Metabolism. 45:117-119.
12. Wilson CB. 1984 A decade of pituitary microsurgery. J Neurosurg. 61:814-833.
13. Chomczynski P, Sacchi N. 1987 Single-step method of RNA isolation by acid guanidium thiocyanate-phenol chloroform extraction. Anal Biochem. 162:156-159.
14. Jaquet P, Gunz G, Grisoli F. 1985 Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions. Horm Res. 22:153-163.
15. Drapper NR, Smith H. 1966 Applied regression analysis selecting the "best" regression equation. New York, London, Sydney: Wiley and Sons; 163-216.
16. Adams EF, Huang B, Buchfelder M, Fahlbusch R. 1997 Preferential expression of mutant gsp alleles in pituitary somatotrophinomas. Proc of the 8th Meet of the Eur Neuroendocrine Assoc. Ann Endocrinol (Paris). 58(Suppl 1):77.
17. Lyons J, Landis CA, Harsh G, et al. 1990 Two G protein oncogenes in human endocrine tumors. Science. 249:655-659.
18. Boothroyd CV, Grimmond SM, Cameron DP, Hayward NK. 1995 G protein mutations in tumours of the pituitary, parathyroid and endocrine pancreas. Biochem Biophys Res Commun. 211:1063-1070.
19. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Itakura M. 1993 Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Cancer. 72:1386-1393.
20. Bertherat J, P Chanson, Montminy M. 1995 The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocinol. 9:777-783.
21. Yang X, Lee FYG, Wand GS. 1997 Increased expression of Gsα enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol. 11:1053-1061.
22. 3 cells expressing constitutively active Gsα (Q227L) show enhanced hormone secretion and proliferation. Mol Cell Endocrinol. 127:41-47.
23. Gaiddon C, Tian J, Loeffler JP, Bancroft C. 1996 Constitutively active Gsα-subunits stimulate Pit-1 promoter activity via a protein kinase A-mediated pathway acting through deoxyribonucleic acid binding sites both for Pit-1 and for adenosine 3′,5′-monophosphate response element-binding protein. Endocrinology. 137:1286-1291.
24. Billestrup N, Swanson LW, Vale W. 1986 Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci USA. 83:6854-6857.
25. Asa SL, Kovacs K, Stefaneanu L, et al. 1992 Pituitary adenomas in mice transgenic for growth hormone-releasing hormone. Endocrinology. 131:2083-2089.
26. Melmed S, Braunstein GD, Horvath E, Ezrin C, Kovacs K. 1983 Pathophysiology of acromegaly. Endocr Rev. 4:271-290.
27. Colao A, Ferone D, Lastoria S, et al. 1996 Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 81:2356-2362.
28. Geffner M, Nagel RA, Dietricht RB, Kaplan SA. 1987 Treatment of acromegaly with a somatostatin analog in a patient with McCune-Albright syndrome. J Pediatr. 111:740-743.
29. Cremonini N, Graziano E, Chiarini V, Sforza A, Zampa GA. 1992 Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long term follow-up, and SMS 201-995-bromocriptine combined treatment results. J Clin Endocrinol Metab. 75:1166-1169.
30. Kelijman M, Williams TC, Downs TR, Frohman LA. 1988 Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly. J Clin Endocrinol Metab. 67:958-963.
31. Reubi JC, Landolt AM. 1989 The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab. 68:844.
32. Patel YC, Greenwood M, Kent G, Panetta R, Skribant CB. 1993 Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun. 192:288-294.